Testing a new immune therapy for advanced cancers and lymphoma

Plain-English translation of NCT05607498 on ClinicalTrials.gov ↗ · Source last updated March 2025 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

This is one of the first times this treatment has been tested in people.

What is this trial?

This is an early-stage trial testing a new medication called EMB-07 in patients with advanced cancers or lymphoma that have not responded to standard treatments. EMB-07 works by connecting your immune system directly to cancer cells, helping your body's own defenses recognize and attack the tumor. Researchers are still learning the safest and most effective dose of this treatment.

Many patients with advanced cancers or relapsed lymphoma run out of treatment options when standard therapies stop working or become too difficult to tolerate. This medication represents a new approach that may help patients whose cancers are resistant to current treatments.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with advanced or metastatic solid tumors (such as breast, lung, ovarian, pancreatic, or colorectal cancer) or relapsed/refractory lymphoma (such as CLL, mantle cell lymphoma, or DLBCL)
you have disease that can be measured on imaging or blood tests
standard cancer treatments are not available to you, no longer work, are too difficult to tolerate, or are not accessible
you are in good enough health to participate (ECOG performance status 0 or 1)
you can provide a tumor sample from the past 2 years or be willing to have a fresh biopsy taken

You likely don't qualify if…

you have already received treatment with a ROR1-targeting medication
you have had severe immune-related side effects (Grade 4) from previous cancer treatments or had to stop a prior therapy because of immune complications
you have cancer in your brain or cancer that has spread to your brain and is causing symptoms (though some patients with brain metastases who have completed radiation may be eligible)
you are currently abusing alcohol, cannabis products, or other drugs
you have received cancer treatment or radiation within the past 4 weeks

What participation looks like

You would receive weekly intravenous infusions of the medication at a medical center. Researchers will start with lower doses and gradually increase them to find the safest and most effective amount — similar to how a doctor might adjust a medication dose over time. You will be closely monitored for side effects and how well the treatment is working through blood tests and imaging scans.

AI-generated summary from trial data · Jun 15, 2026 · Not medical advice

Trial locations(10 sites)

Australia

Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria

One Clinical Research, Nedlands, Western Australia

China

Hunan Cancer Hospital, Changsha, Hunan

Affiliated Hospital of Hebei University, Baoding

Cancer Hospital Chinese Academy of Medical Sciences, Beijing